1	8 If felbamate is used as a concomitant AED participants must be on felbamate for at least 2 years with a stable dose for 8 weeks prior to Visit 1 They must not have a history of white blood cell WBC count below 2500/L 2.50 x 10^9/L platelets below 100,000 liver function tests LFTs above 3 times|felbamate[5,14]|||||||||C0060135|24812|24812|felbamate
1	8 If felbamate is used as a concomitant AED participants must be on felbamate for at least 2 years with a stable dose for 8 weeks prior to Visit 1 They must not have a history of white blood cell WBC count below 2500/L 2.50 x 10^9/L platelets below 100,000 liver function tests LFTs above 3 times|felbamate[68,77]||||2.50[219,223]||x 10[224,228]|2 years[91,98]||C0060135|24812|24812|felbamate
2	the upper limit of normal ULN or other indication of hepatic or bone marrow dysfunction while receiving felbamate If participants received felbamate in the past it must have been discontinued 8 weeks prior to Visit 1|felbamate[401,410]|||||||8 weeks[489,496]||C0060135|24812|24812|felbamate
2	the upper limit of normal ULN or other indication of hepatic or bone marrow dysfunction while receiving felbamate If participants received felbamate in the past it must have been discontinued 8 weeks prior to Visit 1|felbamate[436,445]|||||||||C0060135|24812|24812|felbamate
